Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings
Giuseppe Rossi, Jon Salmanton‐García, Chiara Cattaneo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 98-110
Open Access | Times Cited: 11

Showing 11 citing articles:

Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022
Jon Salmanton‐García, Francesco Marchesi, Francesca Farina, et al.
EClinicalMedicine (2024) Vol. 71, pp. 102553-102553
Open Access | Times Cited: 12
Eosinophils and COVID‐19: Insights into immune complexity and vaccine safety
W. Sahli, Joana Vitte, Benoît Desnues
Clinical and Translational Allergy (2025) Vol. 15, Iss. 3
Open Access
The mode and timing of administrating nutritional treatment of critically ill elderly patients in intensive care units: a multicenter prospective study
Wei Chen, Milin Peng, Ye Z, et al.
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 3
Changes in mortality associated with different hematologic malignancies during the pandemic in the United States
Ugo Fedeli, Claudio Barbiellini Amidei, Xuesong Han, et al.
International Journal of Cancer (2024) Vol. 154, Iss. 10, pp. 1703-1708
Closed Access | Times Cited: 3
Interplay of inflammatory markers and anti-SARS-CoV-2 antibodies in COVID-19 mortality: A prospective cohort study
Sylvia Mink, Heinz Drexel, Andreas Leiherer, et al.
International Journal of Infectious Diseases (2024) Vol. 143, pp. 107016-107016
Open Access | Times Cited: 2
Risk of SARS-CoV-2 infection and severe COVID-19 in hematological patients who received or not pre-exposure prophylaxis with tixagevimab/cilgavimab: a target trial emulation
Marco Falcone, Giusy Tiseo, G. Marchetti, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2024), pp. 1-8
Closed Access | Times Cited: 1
Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA‐EPIFLUEHA Report
Jon Salmanton‐García, Francesco Marchesi, Milan Navrátil, et al.
American Journal of Hematology (2024) Vol. 100, Iss. 3, pp. 358-374
Open Access | Times Cited: 1
Demystifying COVID-19 mortality causes with interpretable data mining
Xinyu Qian, Zhihong Zuo, Danni Xu, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Anti-SARS-CoV-2 Antibodies versus Vaccination Status in CAD Patients with COVID-19: A Prospective, Propensity Score-Matched Cohort Study
Sylvia Mink, Heinz Drexel, Andreas Leiherer, et al.
Vaccines (2024) Vol. 12, Iss. 8, pp. 855-855
Open Access
An overview of SARS-CoV-2 viral proteins with relevance to improved diagnostic and therapeutic platforms
Christopher Chung, Pratiba Irudayaraj, Emran O. Lallow, et al.
Frontiers in Virology (2024) Vol. 4
Open Access
Progressive Cachexia: Tuberculosis, Cancer, or Thyrotoxicosis? Disease-Directed Therapy and Atypical Courses of Autoimmune and Malignant Thyroid Diseases in a High Specialization Era. Case-Control Study with a Critical Literature Review
Przemysław Zdziarski, Zbigniew Sroka
Biomedicines (2024) Vol. 12, Iss. 12, pp. 2722-2722
Open Access
Page 1

Scroll to top